PGR and neoplasm: Competitively inhibits androgen binding to AR, blocking AR nuclear translocation and AR-mediated transcription, resulting in decreased PC cell proliferation and tumor size reduction. It binds more tightly to the AR receptor than other AR antagonists and also acts as a progesterone receptor (PR) antagonist, although the clinical relevance is not fully understood.